Cosmo Bio has revised its full-year earnings forecast for the fiscal year ending December 2026 to net sales of 11,500 million yen (up 0.9% vs. previous forecast) and net income attributable to shareholders of 320 million yen (up 45.5% vs. previous forecast), expecting increased profit driven by yen depreciation and gains from the sale of investment securities.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3386","jir_company_name":"Cosmo Bio Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/3386-20260724-01.pdf","jir_short_summary":"Cosmo Bio has revised its full-year earnings forecast for the fiscal year ending December 2026 to net sales of 11,500 million yen (up 0.9% vs. previous forecast) and net income attributable to shareholders of 320 million yen (up 45.5% vs. previous forecast), expecting increased profit driven by yen depreciation and gains from the sale of investment securities.","jir_summary":"### Summary of Financial Results\nCosmo Bio has revised its full-year earnings forecast for the fiscal year ending December 2026 to net sales of 11,500 million yen (an increase of 100 million yen from the previous forecast) and net income attributable to shareholders of 320 million yen (an increase of 100 million yen from the previous forecast). The increase in sales is driven by steady overseas markets and impacts from yen depreciation, along with gains from the sale of investment securities. Despite considering increased costs and exchange rate fluctuations, the Company continues proactive investments with an outlook for profit growth.\n\n### Future Outlook and Shareholder Impact\nThe depreciating yen and strong overseas sales have led to upward revisions of the full-year sales and net profit forecasts. Particularly, net income has increased by 45.5%, indicating a significant improvement and providing a positive outlook for shareholder returns and future investment activities. The Company plans to continue expanding its global presence and new businesses to strengthen its revenue base.","jir_financial_highlights":"Net Sales: 11,500 million yen (up 0.9% vs. previous forecast)\nNet Income Attributable to Shareholders: 320 million yen (up 45.5% vs. previous forecast)\nOperating Income: 270 million yen (flat)","jir_category":"","jir_hashtags":"#CosmoBio, #EarningsGuidanceRevision, #JapanStocks","jir_key_figures":"Net sales: 11,500 million yen (up 0.9% vs. previous forecast)\nNet income attributable to shareholders: 320 million yen (up 45.5% vs. previous forecast)\nFull-year forecast operating income: 270 million yen (flat)","jir_meta_title":"\u3010Cosmo Bio\u30112026 Full-Year Earnings Guidance Revision | Net Profit Up 45%","jir_meta_description":"Cosmo Bio has revised its full-year earnings forecast for 2026, projecting net sales of 11,500 million yen and net income of 320 million yen. Profit is expected to increase driven by yen depreciation and gains from investment securities sales.","jir_og_title":"\u3010Cosmo Bio\u30112026 Full-Year Earnings Guidance Revision | Net Profit Up 45%","jir_og_description":"Cosmo Bio revised its full-year net income forecast 45% higher to 320 million yen, benefiting from yen depreciation and strong overseas sales. Continued active investments are planned.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59307,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-87778","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n